NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
Neuropace, Inc. (NPCE)
Company Research
Source: GlobeNewswire
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at 3 years.Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS® System, which showed an 82% median reduction in seizures in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE).1 The data were presented in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego from April 5-9, 2025. “Drug-resistant epilepsy is a significant unmet medical need, accounting for up to 30-40% of all epilepsy diagnoses and
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized EpilepsyBusiness Wire
- NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at UBS Group AG from $18.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
NPCE
Earnings
- 11/4/25 - Beat
NPCE
Sec Filings
- 12/15/25 - Form 144
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- NPCE's page on the SEC website